Infliximab

• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Ended
  2023-507405-34-00 Phase III 4 countries Astrazeneca AB
• A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended
  2024-511646-40-00 Phase I/II 1 country AstraZeneca AB
• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime… Ended
  2024-512667-31-00 Phase III 8 countries AstraZeneca AB
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended
  2023-509576-42-00 Phase III 9 countries AstraZeneca AB
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended
  2023-509602-29-00 Phase III 7 countries AstraZeneca AB
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended
  2023-510015-19-00 Phase III 8 countries AstraZeneca AB
• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri… Ended
  2024-510976-19-00 Phase III 6 countries AstraZeneca AB
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos… Ended
  2023-505341-23-00 Phase III 7 countries AstraZeneca AB
• Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. Ended
  2023-509004-15-00 Phase II/III 4 countries AstraZeneca AB
• This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended
  2024-512212-21-00 Phase III 4 countries AstraZeneca AB
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted
  2023-503298-39-00 Phase III 11 countries AstraZeneca AB
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended
  2024-510945-32-00 Phase III 1 country Celltrion Inc.
• PASSPORT Ended
  2023-508584-72-00 Phase III 1 country Centre Medico Chirurgical Ambroise Pare Hartmann
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 Phase II 5 countries AstraZeneca AB
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Ended
  2022-502773-41-00 Phase I/II 4 countries AstraZeneca AB
• A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with lo… Ended
  2023-509053-32-00 Phase III 3 countries AstraZeneca AB
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended
  2022-502747-35-00 Phase III 12 countries AstraZeneca AB
• Study of durvalumab/placebo + chemoradiation therapy in Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer Ended
  2024-515321-29-00 Phase III 2 countries AstraZeneca AB
• Study of First Line MEDI4736 with or without Tremelimumab versus Standard of Care Chemotherapy in Advanced Unresectable Urothelial Cancer. Ended
  2024-513399-17-00 Phase III 2 countries AstraZeneca AB
• Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to s… Ended
  2023-507450-32-00 Phase III 1 country Medical University Of Gdansk
• Medical research to compare the effectiveness of infliximab injections alone or in combination with immunosuppressive drugs in the treatment… Ended
  2024-517171-20-00 Phase IV 1 country Amsterdam UMC Stichting

Showing 73–93 of 93 trials